کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2136515 1087794 2015 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia
ترجمه فارسی عنوان
فعالیت بالینی آلووسییدیب (فلووپیریدول) در لوسمی میلوئیدی حاد
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی
There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory. Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clinical activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone). FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, respectively, with encouraging findings in both patient populations warranting further investigation. This review highlights the mechanism of action of alvocidib, pre-clinical studies of alvocidib in AML, and the clinical trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 39, Issue 12, December 2015, Pages 1312-1318
نویسندگان
, ,